For U.S. Healthcare Professionals
OPSUMIT® (macitentan) video library
Explore an informative video series around the professional and patient perspectives on PAH featuring Lindsay, a patient living with PAH who has been taking OPSUMIT® since 2013.
Individual patient experience may vary. OPSUMIT® has a 9-year long-term safety, tolerability, and survival open-label extension study in patients with PAH.1
Lindsay's path to a PAH specialist
Lindsay recounts an experience that highlights the significance of a supportive healthcare team. Dr McConnell talks about the importance of getting to know patients and their families.
PAH=pulmonary arterial hypertension.
Reference:
1. Souza R, Delcroix M, Galié N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374-4390